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Introduction: Circulating tumor microemboli (CTM) are potentially 
important cancer biomarkers, but using them for cancer detection in 
early-stage disease has been assay limited. We examined CTM test per-
formance using a sensitive detection platform to identify stage I non–
small-cell lung cancer (NSCLC) patients undergoing imaging evaluation.
Methods: First, we prospectively enrolled patients during 18F-FDG 
PET-CT imaging evaluation for lung cancer that underwent routine 
phlebotomy where CTM and circulating tumor cells (CTCs) were 
identified in blood using nuclear (DAPI), cytokeratin (CK), and 
CD45 immune-fluorescent antibodies followed by morphologic iden-
tification. Second, CTM and CTC data were integrated with patient 
(age, gender, smoking, and cancer history) and imaging (tumor diam-
eter, location in lung, and maximum standard uptake value [SUV
max
]) 
data to develop and test multiple logistic regression models using a 
case-control design in a training and test cohort followed by cross-
validation in the entire group.
Results: We examined 104 patients with NSCLC, and the subgroup 
of 80 with stage I disease, and compared them to 25 patients with 
benign disease. Clinical and imaging data alone were moderately 
discriminating for all comers (Area under the Curve [AUC] = 0.77) 
and by stage I disease only (AUC = 0.77). However, the presence 
of CTM combined with clinical and imaging data was significantly 
discriminating for diagnostic accuracy in all NSCLC patients (AUC 
= 0.88, p value = 0.001) and for stage I patients alone (AUC = 0.87, 
p value = 0.002).
Conclusion: CTM may add utility for lung cancer diagnosis during 
imaging evaluation using a sensitive detection platform.
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(J Thorac Oncol. 2014;9: 1111–1119)
Despite the mortality benefit demonstrated by the National Lung Screening Trial,1 there remain concerns about the 
cost of delivering care for patients identified with a lung nod-
ule given the 96% false positive rate from the study, and the 
unnecessary procedures resulting from inaccurately risk-strat-
ified nodules using existing prediction models.2 Blood bio-
markers have transformative potential by correctly identifying 
patients who may benefit from treatments with curative intent 
rather than from watchful waiting.3
CTCs represent one potential advance with direct clini-
cal application given their noninvasive measurement from 
blood. Although CTCs have been reported in the literature 
since the 19th century primarily as pathologic curiosities,4–6 
in 2004 the Food and Drug Administration’s approval of CTC 
enumeration using an immuno-bead antibody capture platform 
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(CellSearch; Janssen Diagnostics, Raritan, NJ) advanced the 
field significantly.7,8 CellSearch was the first technology to 
demonstrate clinical utility by standardizing the CTC plat-
form, and prospective, observational data have confirmed that 
CTC burden is related to therapeutic response and prognosis 
in multiple types of late-stage cancers.9,10 CTC detection in 
early-stage disease using CellSearch, however, has been less 
promising due to poor detection sensitivity resulting from 
suboptimal epithelial cell adhesion molecule (EpCAM) affin-
ity and tumor cell heterogeneity.11–13
More technically sensitive rare cell platforms exist 
that enrich CTC populations by both EpCAM-dependent14 
and EpCAM-independent techniques,15–17 with the ability 
to detect a two to three log-fold increase in CTCs for non-
metastatic cancers. Our group has previously reported that the 
“High Definition” Circulating Tumor Cell (HD-CTC) plat-
form, which takes advantage of well-established cell mark-
ers (DAPI, CK, and CD45) and rapid, automated fluorescence 
microscopy to identify CTCs by morphology rather than by 
EpCAM affinity, may be more sensitive than EpCAM-based 
detection systems.18
In multiple studies over the past decade, we have found 
that the HD-CTC platform detects large quantities of puta-
tive CTCs in metastatic breast, lung, and prostate cancers,18–21 
with prognostic discrimination in non–small-cell lung cancer 
(NSCLC).21 During these studies, we noted that CTCs were 
detected in high quantities in several early-stage NSCLCs,22 
and that tumor cell aggregates (or circulating tumor “micro-
emboli,” [CTM]) were omnipresent across diverse cancers.23 
We further discovered that CTCs and CTM were not always 
related to a tumor’s size or metabolic activity in stage I cancers 
or across all stages.24 These observations led us to investigate 
whether CTCs and CTM are not only detectable in stage I 
NSCLC, but also if they are complementary to current clini-
cal models of risk2 and could aid as a noninvasive diagnostic.
Current methods for risk-stratifying nodules and iden-
tifying lung cancer in patients focus on basic demographic 
variables (i.e., age, cancer, and smoking history),25 CT imag-
ing26,27 and, for nodules greater than 8 mm in size, FDG 
PET-CT imaging.25,28 To date, rare cell assays have not been 
well studied for risk-stratifying larger lung nodules to deter-
mine whether CTM could be helpful diagnostic adjuncts. We 
explore here whether adding CTC data to existing clinical 
and imaging information could enhance diagnostic accuracy 
by analyzing patients who underwent evaluation with FDG 
PET-CT imaging during a lung cancer evaluation in a case-
control study design.
METHODS
Study Design
CTC analysis was performed in the context of a multi-
center, prospective, observational study of CTCs in patients 
with a lung nodule or mass who underwent 18F-FDG PET-CT 
imaging for lung cancer evaluation. At or near to the time of 
PET-CT imaging, patients were enrolled at one of five medical 
centers: two US tertiary referral academic centers, Stanford 
and the University of California San Diego (UCSD); two 
US community hospitals, The Billings Clinic and California 
Pacific Medical Center (CPMC); and one US veteran’s hospi-
tal, the VA Palo Alto Health Care System (PAVAHCS). Three 
of these medical centers (Stanford, CPMC, PAVAHCS) aimed 
to investigate localized disease (i.e., tumors less than 4 cm in 
size), whereas the other two (The Billings Clinic and UCSD) 
were enrolling patients with more advanced disease who were 
undergoing medical oncology evaluation. Cases were defined 
by having NSCLC and controls defined as patients who under-
went PET-CT but ultimately were diagnosed with a compet-
ing, benign diagnosis. Research at all participating facilities 
was approved by their respective institutional review board, 
and all patients were enrolled using informed consent accord-
ing to the principles embodied in the Declaration of Helsinki.
Patient whole blood was collected into 10 ml Streck Cell 
Free DNA BCT (Streck, Omaha, NE) through a peripheral, 
upper extremity vein after discarding the first one milliliter 
to minimize skin tag contamination. Samples were shipped at 
ambient temperature and processed at The Scripps Research 
Institute (TSRI) within 48 hours. Before data analysis and 
integration of diagnosis with CTC data, the interpretation 
of the High-Definition Circulating Tumor Cell (HD-CTC) 
assay was performed without knowledge of the diagnosis in 
a single-blinded approach. We referred to the PRoBE bio-
marker guidelines to follow best practices during this study’s 
execution.29
Cohort Development
Patients were analyzed as two separate cohorts for split-
sample validation using the first set of consecutively enrolled 
patients undergoing FDG PET-CT imaging and CTC analy-
sis as the training group and the next set of consecutively 
enrolled patients undergoing FDG PET-CT imaging who had 
CTC analysis performed as the test group. Since the HD-CTC 
test is not specific to lung cancer alone,18,22 any patient who 
had a competing diagnosis of another non-lung cancer, 
defined as undergoing evaluation or current treatment for it, 
was excluded to eliminate diagnostic confounding. All blood 
was drawn before any treatment for lung cancer and within 90 
days of PET-CT. All medical centers used the same enrollment 
criteria, phlebotomy protocols, blood processing protocols, 
and clinical extraction parameters. Please note that we have 
previously published data for a subgroup of patients (n = 50) 
reported here regarding CTC enumeration and its association 
with tumor FDG uptake.24
Data Extraction
We extracted clinical data including age, gender, ethnic-
ity, cancer history, and smoking status. A patient was defined 
as a current smoker if they were smoking at the time of enroll-
ment, past smoker if they ever reported smoking and were 
not smoking at the time of enrollment, and nonsmoker if they 
never smoked. Patients were followed over time through June 
1, 2013, at all centers (median time 12.3 months, interquartile 
range [IQR] 3.7–16.7 months) and characterized as definitively 
malignant or benign, unknown, or lost to follow-up. NSCLC 
was determined by biopsy and/or surgery (n = 102), or clini-
cal grounds (n = 2 patients). Benignity was defined by the 
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extracting physician (V.S.N., G.H., L.B., and J.N.) after review-
ing the medical record and included patients who had surgi-
cally resected nodules that were not cancer (n = 7), a biopsy 
yielding an alternative diagnosis (n = 6), nodules that dimin-
ished over time with or without noncancer-related treatments 
(n = 7), or radiographic benign nodules per report (n = 5).
Staging of cancer was extracted from the medical 
chart and defined by the most recent TNM staging system 
(American Joint Committee on Cancer [AJCC] v 7.0).30 
Imaging data collected included maximum standard uptake 
value (SUV
max
) of the lesion, maximum nodule diameter, and 
tumor location. For lung region, we analyzed upper and lower 
lung zones; right middle lobe tumors were classified as lower 
lung zone tumors. We did not partial volume correct for tumor 
SUV
max
31 to simulate the clinical setting.
CTM Classification and CTC Enumeration
Detailed sample analysis for CTM and CTCs was per-
formed as reported previously.18 The technologist, micro-
scopes, and analysis systems were constant throughout this 
study. Blood samples underwent hemolysis, centrifugation, 
re-suspension, and plating onto four custom adhesion slides 
(Marienfeld, Lauda, Germany), followed by −80°C stor-
age. The amount of blood plated onto slides was guided by 
a cell counter (Medonic M-Series Hematology Analyzer; 
Stockholm, Sweden) to approximate 10 million nucleated 
cells so as not to “underload” or “overload” the slide set, rep-
resenting 1.5 ml of whole blood on average per sample.
Before analysis, slides were thawed, labeled by immuno-
fluorescence (pan cytokeratin, CD45 and DAPI),18 and imaged 
by automated fluoroscopy. This was followed by manual vali-
dation by a pathology-trained technician (MSL). Morphology 
along with DAPI (+), CK (+), and CD45(−) intensities were 
defined for each channel to identify HD-CTCs as previously 
described (Fig. 1).21 Cells that only partially met criteria were 
not deemed to be an HD-CTC by the technologist but were 
recorded as well. This included cells that were smaller than an 
accepted HD-CTC (“Small” HD-CTC Candidates or SHCs) 
or dimmer by CK staining than a HD-CTC (“Dim” HD-CTC 
Candidates or DHCs). Thus, the HD-CTC platform was able 
to categorize HD-CTC populations and unique “CTC like” 
candidate cells for analysis as previously described.21
For circulating tumor microemboli (HD-CTM) evalu-
ation, we defined groups of two HD-CTCs or more with 
touching cytoplasm as an HD-CTM over the same area.23 
HD-CTMs were enumerated, the number of cells in HD-CTM 
were defined by the nuclei within them (using the DAPI coun-
terstain), and HD-CTMs were then dichotomized as either 
present or not for further analysis.
Statistical Analysis
Summary statistics and frequencies were generated as 
appropriate. Continuous variables are reported as their median 
and IQR for both parametric and nonparametric distributions. 
Differences between patients with NSCLC and benign nod-
ules, as well as stage I disease only and benign lesions, were 
compared using a Student’s t test, Wilcoxon log-rank test, χ2 
test, Fisher’s exact test, or Kruskal–Wallis test as appropriate 
and were annotated for a p value less than 0.05. Differences 
in HD-CTCs/CTM for other groups (i.e., time to biopsy, cen-
ter, or histology) were also analyzed using the above tests as 
appropriate. For differences by histology, we grouped all non-
adenocarcinomas together.
To analyze which HD-CTC assay derived features added 
value in addition to clinical and FDG PET-CT data, we cali-
brated several multiple logistic regression models using can-
didate HD-CTC derived variables. We also employed a Lasso 
model32 to agnostically select important HD-CTC features. The 
variables included for modeling were clinically derived (four 
total): age, sex, smoking, and cancer history; FDG PET-CT 
derived (three total): SUV
max
, maximum lesion diameter, and 
lesion location; and HD-CTC assay derived (seven total): 
HD-CTCs, HD-CTM, and HD-CTC candidate cell features. 
Cell features and enumerated thresholds for determining malig-
nant from benign disease were generated to optimize the accu-
racy of the HD-CTC test alongside traditional, clinical, and 
imaging parameters of risk for a solitary pulmonary nodule.2 
Statistically significant variables were then carried forward to 
a test set of patients (n = 41) to confirm their importance in the 
model, in addition to being analyzed in the entire cohort.
Receiver operating characteristic (ROC) curves were 
generated to illustrate the performance of each model for 
distinguishing benign patients from all NSCLC patients or 
stage I patients only. These are reported in the results as the 
area under the curve (AUC) with 95% confidence intervals 
(CIs), where CIs for the ROC curves was calculated using the 
R package pROC.33 From this, we report model sensitivity 
and specificity in the training, test, and full data sets. We also 
report the likelihood ratios (LRs), positive predictive value 
(PPV), and negative predictive value (NPV) for CTM using a 
2 × 2 contingency table.
For determining significant differences between mod-
els, the function roc.test () from the pROC package was used 
with bootstrapping (n = 1000). Results were also validated in 
all patients using 10-fold cross-validation (CV) to determine 
model stability.34 For this analysis, we considered CIs that 
did not overlap between models as a statistically significant 
result. This analysis was performed for all NSCLC cases 
and for stage I disease only versus benign cases. Lastly, risk 
scores for the most significant models were developed using 
all patients with the coefficients (ß) representing the contri-
bution of the variable (x) to the risk model as follows:
y X +0 1 n n= + …+ß ß X ß1  1
where the probability of cancer is equivalent to:
e  1  ey y/ +( )  2
All analyses were performed using SAS Enterprise Guide 
(v 4.3; Cary, NC) and R (v 3.0.1).35
RESULTS
Study Cohort
A total of 170 patients who underwent phlebotomy for 
CTC analysis were assessed in this study (Fig. 2). Ultimately, 
1114 Copyright © 2014 by the International Association for the Study of Lung Cancer
Carlsson et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 8, August 2014
129 patients were eligible for further analysis after CTC 
assaying, diagnostic verification, and elimination of con-
founding cancers (Fig. 2). Of these 129 patients, 104 had a 
diagnosis of NSCLC and 25 had a benign diagnosis (Table 1). 
Of the 104 NSCLC patients, 80 had a diagnosis of stage I 
disease, whereas the remaining 24 had stage II–IV disease. 
The training cohort (n = 88) consisted of 71 cases (54 stage 
I patients) and 17 controls whereas the test cohort (n = 41) 
consisted of 33 cases (26 stage I patients) and 8 controls.
For all comers, median age was 69 years (IQR 11 years), 
84% of patients were current or past smokers, and 63% of patients 
were male (Table 1). Overall lesion size for 104 NSCLCs and 25 
benign lesions was 2.2 cm (IQR 1.4 cm) and the SUV
max
 was 4.5 
(IQR 7.0). Eighty of the NSCLCs were stage I, whose predomi-
nant histology was adenocarcinoma (68%).
Significant differences existed between benign and 
malignant groups for age, tumor location, SUV
max
, HD-CTC 
counts, and HD-CTM, whereas the training and test cohorts 
differed only in gender (Table 1). Training and test cohorts did 
not differ significantly by stage or histology. Notably, lesion 
size was not different between diagnostic groups but SUV
max
 
was. Although 69 patients had a biopsy before treatment and 
41 patients had a biopsy preceding phlebotomy for HD-CTC 
analysis (10 within 1 week preceding phlebotomy), there was 
no association between proximity of biopsy to blood draw for 
HD-CTC counts (p = 0.46) or HD-CTM (p = 0.62).
CTM and CTC Detection
The amount of whole blood analyzed for HD-CTM 
and HD-CTC detection was approximately 1.5 ml, and this 
did not vary by diagnosis or cohort (Table 1). A total of 4291 
HD-CTCs were discovered in malignant disease (n = 104) 
versus 65 in benign disease (n = 25) and HD-CTCs ranged 
from 0 to 378 in the malignant group and from 0 to 16 in the 
benign group (Supplemental Table 1 and Supplemental Fig. 1, 
SDC1, http://links.lww.com/JTO/A622). HD-CTM ranged 
from 0 to 184 for malignant patients and 0 to 2 for benign 
lesions. (Supplemental Table 1 and Supplemental Fig. 1, 
SDC1, http://links.lww.com/JTO/A622).
For stage I tumors only, HD-CTCs ranged from 0 to 297 
and HD-CTM ranged from 0 to 104. Of the 104 patients, 52 
(50%) had HD-CTM for all NSCLCs, and 39 of 80 patients 
(49%) had HD-CTM in stage I disease only. There were no dif-
ferences by histology or stage grouping for HD-CTC counts 
(p = 0.22 and 0.39, respectively) or HD-CTM (p = 0.22 and 
0.65, respectively). No differences by enrollment center for 
HD-CTCs (p = 0.54) or HD-CTM (p = 0.86) were evident either.
Logistic Regression Models
Clinical variables, imaging features on PET-CT, and 
HD-CTCs/CTM in blood as individual predictors identified can-
cer patients with only marginal discrimination (AUC = 0.65–0.70). 
Inline with the existing literature,2 clinical and imaging data 
FIGURE 1.  Circulating tumor cells 
and CTM used for modeling. Panel 
(A) shows the composite image for 
an HD-CTC from a patient with stage 
I adenocarcinoma followed by the 
individual DAPI positive (Blue, B), 
Cytokeratin positive (Red, C), and 
CD45 negative (Green, D) chan-
nels defining the cell. A doublet 
(Panels E–H), triplet (Panels I–L), 
and “mega” cluster of more than 8 
HD-CTCs (Panels M–P) are shown as 
composites and by individual chan-
nels. HD-CTM were defined as more 
than one HD-CTC with touching 
cytoplasm (see Methods) for further 
modeling.
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together yielded reasonable accuracy for a diagnosis of any NSCLC 
versus benign disease, or for stage I versus benign disease across 
training and test cohorts (Table 2). Notably, age, maximal tumor 
diameter on CT, and tumor SUV
max
 had the largest impact on the 
clinical model for all NSCLC patients and by stage I disease only 
(Supplemental Table 2, SDC1, http://links.lww.com/JTO/A622).
CTM alone had a positive LR of 10, negative LR of 0.5, 
PPV of 96%, and NPV of 31% for identifying NSCLC assuming 
a cancer prevalence documented in this cohort of 81%. Based on 
the superior diagnostic performance of HD-CTM (AUC = 0.70) 
over HD-CTC (AUC = 0.65) for diagnosis we assessed whether 
HD-CTM (present or absent) enhanced performance significantly 
when compared with the clinical diagnostic model alone (Table 2, 
Fig. 3). Ten-fold cross-validation confirmed that HD-CTM signif-
icantly added information to the clinical model when including all 
comers, or when restricting the analysis to stage I patients alone or 
those with stage I tumors smaller than 3 cm (Table 3).
We then proceeded to develop a risk score using the 
HD-CTM model’s coefficients (Supplemental Table 2, SDC1, 
http://links.lww.com/JTO/A622) for the relevant variable lev-
els defined in Table 1:
y 6 79 1 6 Age 524 Gender  
327 Smoking History
= ( ) ( )
( )
− + −
+
. . .
.
0 0 0
0 −
+ −
0.441 Cancer History  
0.184(SUVmax) 0.425(Tumor Diamet
( )
er) 
1.05(Tumor Location) 2.54(HD-CTM)+ +
 3
We also plotted individual patient risk to graphically 
illustrate the utility of this score for diagnostic refine-
ment above and beyond clinical data (Supplemental Fig. 
2, SDC1, http://links.lww.com/JTO/A622). Finally, we 
confirmed that HD-CTM were important features in aug-
menting diagnosis when using the agnostic Lasso model 
that selected age, SUV
max
, and HD-CTC as the most impor-
tant features for diagnosis from 14 entry variables in 
training, test, and all groups (Supplemental Fig. 3, SDC1, 
http://links.lww.com/JTO/A622).
DISCUSSION
We demonstrate here the diagnostic utility of an EpCAM-
independent CTC platform assay that utilizes 1–2 ml of whole 
blood at room temperature within 48 hours of phlebotomy in 
a patient cohort undergoing PET-CT imaging for lung cancer 
evaluation. Although many investigators have been interested 
in using CTCs as prognostics in cancer, including NSCLC, 
we show that CTM may be a viable diagnostic when added 
to integrated clinical and imaging data in early-stage disease, 
and further, develop a risk score for diagnosis. To illustrate 
the utility of this score, we give the hypothetical example of a 
71-year-old male former smoker, with no cancer history and a 
1.7-cm lower lobe nodule whose FDG PET-CT SUV
max
 is 2.0 
and whose blood reveals HD-CTM. Applying Equation 3 and 
variable coefficients given in Supplemental Table 2 (SDC1, 
http://links.lww.com/JTO/A622), we see that this patient 
FIGURE 2.  Patient flow. This was 
a prospective, observational study 
of patients undergoing evaluation 
for lung cancer by FDG PET-CT that 
had blood drawn for CTC analysis. 
We excluded patients with blood 
processing errors, those without a 
definitive benign or non–small-cell 
lung cancer diagnosis, and those 
with concurrent cancers. Clinical, 
imaging, and CTC variables of inter-
est were explored in a training set  
(n = 88) and validated in a test set 
(n = 41) for all patients and for the 
stage I subgroup only.
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would increase his pretest probability of cancer from 58% to 
89% with the addition of CTM data.
Although Tanaka et al.12 performed an important study 
using a similar patient cohort, they were unable to find a dis-
criminating model using CTCs, and they did not integrate clini-
cal or imaging data during analysis. Their negative results may 
be in part due to 1) sensitivity limitations of the CellSearch plat-
form compared to the HD-CTC platform—since it is dependent 
on EpCAM antibody affinity—and/or 2) the lack of compari-
son to standard clinical variables of risk for identifying NSCLC 
patients, since orthogonally related biomarkers like FDG PET 
and CTCs24 appear to have additive value in our models.
The most discriminating models in our study included 
CTM. The rarity of such disease derived cell clusters, ranging 
from a few cells aggregated together to “mega-clusters,” and 
recent molecular characterizations describing their EMT 
phenotype suggest that clusters may be a more “cancerous” 
subtype of putative CTCs.13,36,37 Our data recapitulated this 
clinically as CTM were the strongest diagnostic in our models 
using not only a candidate-driven approach, but when employ-
ing a lasso model that agnostically selected CTM as the most 
important HD-CTC feature along with other clinical data.
All diagnostic tests have limited sensitivity and speci-
ficity, whether novel or decades old. Original data published 
using CellSearch were remarkably discriminatory when using 
healthy patients and nonmalignant disease controls,38 but even 
this data suggested nonmalignant disease resulted in more 
false positive results. Additional recent studies have suggested 
TABLE 1.  Cohort Characteristicsa
All Patients Training Cohort Test Cohort
All (n = 129) Benign (n = 25) Malignant (n = 104)
71 Malignant; 17 
Benign (n = 88)
33 Malignant; 8 
Benign (n = 41)
Clinical data Age (years) 69 ± 11 65 ± 12b 69 ± 11b 68 ± 12 70 ± 12
Gender (male) 81 (63) 17 (68) 64 (62) 63 (72)b 18 (44)b
Smoking historyc
None 21 (16) 6 (24) 15 (14) 15 (17) 6(15)
Past 78 (60) 13 (52) 64 (62) 48 (55) 29 (71)
Current 31 (24) 6 (24) 25 (24) 25 (28) 6 (15)
Cancer history (yes) 51 (40) 13 (52) 38 (37) 38 (43) 13 (32)
Upper Lobe 72 (56) 10 (40)b 62 (60)b 50 (57) 22 (54)
Lesion size (cm)d 2.2 ± 1.4 2.1 ± 2.3 2.2 ± 1.3 2.3 ± 1.8 2.3 ± 1.4
SUV
max
4.5 ± 7.0 2.6 ± 2.1b 5.2 ± 6.2b 4.0 ± 7.0 5.3 ± 5.7
Stage I disease 80 (62) 80 (77) 54 (61) 26 (66)
CTC data Time to assay (hr) 24 ± 2 23 ± 4 24 ± 2 24 ± 3 24 ± 2
mls processed 1.5 ± 0.8 1.5 ± 1.1 1.4 ± 0.7 1.4 ± 0.8 1.4 ± 0.6
HD-CTCse 3.6 ± 15 0.7 ± 4.0b 4.8 ± 19b 3.7 ± 11 3.7 ± 10
HD-CTM (yes/no) 54 (42) 2 (8)b 52 (50)b 35 (40) 18 (44)
aContinuous variables shown with interquartile range (IQR, 25–75% range) for parametric and nonparametric variables. Differences between groups were tested using a Student’s 
t test or Wilcoxon log-rank test for parametric and nonparametric variables, respectively. Categorical or ordinal variables were compared using χ2 test, Fisher’s exact test, or Kruskal–
Wallis testing as appropriate.
bSignificant differences by diagnosis at the p < 0.05 level.
cDefined as current, ever, or never per chart review.
dLongest axis on PET-CT.
eStandardized count per 10 million nucleated cells (i.e., white blood cells or WBC). 
Cm, centimeter; SUV
max
, maximum standard uptake value; ml, milliliters; hr, hours.
TABLE 2.  Performance of Clinical and HD-CTM Models
NSCLC vs. Benign Stage I vs. Benign
Training (n = 88) Test (n = 41) All (n = 129) Training (n = 71) Test (n = 34) All (n = 105)
AUC 0.78 (0.68–0.89) 0.75 (0.53–0.97) 0.77 (0.68–0.87) 0.80 (0.68–0.91) 0.76 (0.54–0.97) 0.79 (0.68–0.87)
Clinical variables onlya Sens 0.65 0.91 0.71 0.83 0.85 0.68
Spec 0.88 0.63 0.80 0.71 0.63 0.84
AUC 0.88 (0.81–0.96) 0.88 (0.66–0.99) 0.88 (0.82–0.94) 0.88 (0.79–0.97) 0.88 (0.75–1.00) 0.87 (0.82–0.94)
Clinical and HD-CTMb Sens 0.79 0.72 0.82 0.82 0.78 0.83
Spec 0.88 1.00 0.84 0.88 1.00 0.84
aSee Table 1 for variables and levels included in the clinical model.
bSee Supplemental Table 2 for significant variables in each model. Models that significantly add value to the clinical model are in bold.
AUC, area under curve (C-statistic) with 95% confidence interval; sens, sensitivity; spec, specificity.
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an increased number of false positive results in patients 
with competing diagnoses undergoing a work-up for colon 
and lung cancer.12,39 Furthermore, studies assessing single 
cell genomics that require more rigor when identifying cells 
have documented the need to purify putative “CTCs” using 
CellSearch resulting from up to a 30% false positive rate.40
We also found that, unsurprisingly, the HD-CTC assay 
will detect CTC-like events in high-risk patients with other 
competing diagnoses (Supplemental Table 1, SDC1, http://
links.lww.com/JTO/A622). This suggests that, although enu-
meration appears to be clinically useful, even sensitive meth-
ods for detecting CTCs will benefit from additional molecular 
characterization to differentiate circulating epithelial cells 
(CECs) from CTCs regardless of platform type. Using addi-
tional protein biomarkers, next generation sequencing for 
single mutational or whole genome copy number variation 
analysis to define cells with pathognomonic hallmarks of can-
cer is one way to approach this issue that we are currently 
investigating. Whether inconsequential CECs arise from com-
peting inflammatory lesions other than lung cancer or clini-
cally undetected premalignant lesions remains a question that 
will be answered over time as the patient cohort matures.
A B C
D E F
FIGURE 3.  HD-CTM integrated with clinical and imaging data improve diagnostic accuracy for NSCLC. Receiver operating 
characteristic (ROC) curves for diagnostic models calibrated using the training set and carried forward to the test set are shown. 
Models A–C were trained and tested using all comers, whereas D–F used stage I cancers only. Each plot displays the perfor-
mance of two models (clinical alone and with CTM) and a p value estimating the significance of the difference between the 
ROC curves. The ROC AUCs and their confidence intervals are given in the bottom right corner of each plot.
TABLE 3.  Cross-Validation of Models for NSCLC Patients 
and Stage I Disease
Model AUC (95% CI)
NSCLC, Clinical only (n = 129) 0.72 (0.70–0.75)
NSCLC, Clinical and HD-CTM (n = 129) 0.81 (0.77–0.84)
Stage I, Clinical only (n = 104) 0.71 (0.68–0.74)
Stage I, Clinical and HD-CTM (n = 104) 0.80 (0.76–0.83)
T1 Subgroup, Clinical only (n = 81) 0.63 (0.55–0.71)
T1 Subgroup, Clinical and HD-CTM (n = 81) 0.75 (0.72–0.79)
Bolded AUCs are significantly different from the baseline model. T1 subgroup 
represents stage I tumors smaller than 3 cm (n = 56) compared to benign lesions (n = 25).
NSCLC, non–small-cell lung cancer; CI, confidence interval.
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Finally, although we believe consecutive enrollment of 
patients who underwent PET-CT and CTC analysis at multiple 
centers across the western United States is a strength of this 
study, we acknowledge that its observational nature may have 
led to several biases in the collection of the data that render 
its findings preliminary. These include (1) an inherent spec-
trum bias at participating centers; (2) the inclusion of patients 
who only underwent PET-CT that may have led to identifying 
larger benign lesions (i.e., higher risk lesions, see Supplement 
Figures 1 and 2, SDC1, http://links.lww.com/JTO/A622) than 
one would normally see in an evaluation setting; and (3) an 
additional bias toward identifying larger benign lesions that 
had a more expeditious work-up compared to smaller lesions 
that remain indeterminate (and thusly excluded from our anal-
ysis) and are being followed over time.
CONCLUSION
Putative CTM detected using standard cell markers 
and cell morphology in the HD-CTC platform were use-
ful for risk-stratifying patients undergoing an evaluation for 
lung cancer and augmented clinical models alone. Although 
strict enumeration of this important blood biomarker appears 
to be clinically useful in the appropriate patient population, 
special attention is required in high-risk populations since 
CECs resulting from nonmalignant conditions may alter test 
performance. Advancing fluid biopsies originally developed 
for disease monitoring in patients with cancer into the setting 
of primary diagnosis requires additional validation and refine-
ment of test performance in larger cohorts before prospective 
trials to establish clinical utility.
ACKNOWLEDGMENTS
The authors thank the Molecular Imaging Program 
and MultiModality Imaging Laboratory at Stanford; Pragya 
Tripathi, Julie Loero, and the Nuclear Medicine Staff at 
the PAVAHCS; Claude James at the UCSD Moores Cancer 
Center; Steve Wharton and Tricia Montgomery at The Billings 
Clinic; Benjamin Luna and Jamey Schmidt at the CPMC 
Research Institute; Daniel Lazar, Thomas Metzner, Rachelle 
Lamy, Loressa Uson, Julia Li, Luisa Fernandez Altuna, 
Natalie Felch, Janett Stoehr, Nadia Ebrahim, and Newsha 
Sahaf at TSRI. Lastly, to our patients who consented for this 
study, we thank you for advancing our understanding of early-
stage lung cancer.
REFERENCES
 1. Aberle DR, Adams AM, Berg CD, et al.; National Lung Screening Trial 
Research Team. Reduced lung-cancer mortality with low-dose computed 
tomographic screening. N Engl J Med 2011;365:395–409.
 2. Schultz EM, Sanders GD, Trotter PR, et al. Validation of two models to 
estimate the probability of malignancy in patients with solitary pulmo-
nary nodules. Thorax 2008;63:335–341.
 3. Li XJ, Hayward C, Fong PY, et al. A blood-based proteomic classifier 
for the molecular characterization of pulmonary nodules. Sci Transl Med 
2013;5:207ra142.
 4. Asworth T. A case of cancer in which cells similar to those in the tumours 
were seen in the blood after death. Australian Med J 1869;14:146–147.
 5. Takahashi M. An experimental study of metastasis. J Pathol Bacteriol 
1915;20:1–13.
 6. Romsdahl MD, Chu EW, Hume R, Smith RR. The time of metastasis and 
release of circulating tumor cells as determined in an experimental sys-
tem. Cancer 1961;14:883–888.
 7. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, dis-
ease progression, and survival in metastatic breast cancer. N Engl J Med 
2004;351:781–791.
 8. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a 
novel prognostic factor for newly diagnosed metastatic breast cancer. J 
Clin Oncol 2005;23:1420–1430.
 9. Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-
metastatic breast cancer: a prospective study. Lancet Oncol 2012;13: 
688–695.
 10. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic signifi-
cance of circulating tumor cells in patients with non-small-cell lung can-
cer. J Clin Oncol 2011;29:1556–1563.
 11. Tanaka F YK, Hasegawa S. Circulating tumor cells (CTCs) in lung can-
cer: current status and future perspectives. Lung Cancer: Targets and 
Therapy. 2010;1:77–84.
 12. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic 
marker in primary lung cancer. Clin Cancer Res 2009;15:6980–6986.
 13. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit 
dynamic changes in epithelial and mesenchymal composition. Science 
2013;339:580–584.
 14. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulat-
ing tumour cells in cancer patients by microchip technology. Nature 
2007;450:1235–1239.
 15. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell 
detection using the isolation by size of epithelial tumor cell method for 
patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 
2011;17:827–835.
 16. Krivacic RT, Ladanyi A, Curry DN, et al. A rare-cell detector for cancer. 
Proc Natl Acad Sci U S A 2004;101:10501–10504.
 17. Kuhn P, Bethel K. A fluid biopsy as investigating technology for the fluid 
phase of solid tumors. Phys Biol 2012;9:010301.
 18. Marrinucci D, Bethel K, Kolatkar A, et al. Fluid biopsy in patients 
with metastatic prostate, pancreatic and breast cancers. Phys Biol 
2012;9:016003.
 19. Marrinucci D, Bethel K, Luttgen M, Bruce RH, Nieva J, Kuhn P. 
Circulating tumor cells from well-differentiated lung adenocarcinoma 
retain cytomorphologic features of primary tumor type. Arch Pathol Lab 
Med 2009;133:1468–1471.
 20. Lazar DC, Cho EH, Luttgen MS, et al. Cytometric comparisons between 
circulating tumor cells from prostate cancer patients and the prostate-
tumor-derived LNCaP cell line. Phys Biol 2012;9:016002.
 21. Nieva J, Wendel M, Luttgen MS, et al. High-definition imaging of circu-
lating tumor cells and associated cellular events in non-small cell lung 
cancer patients: a longitudinal analysis. Phys Biol 2012;9:016004.
 22. Wendel M, Bazhenova L, Boshuizen R, et al. Fluid biopsy for circulat-
ing tumor cell identification in patients with early-and late-stage non-
small cell lung cancer: a glimpse into lung cancer biology. Phys Biol 
2012;9:016005.
 23. Cho EH, Wendel M, Luttgen M, et al. Characterization of circulating 
tumor cell aggregates identified in patients with epithelial tumors. Phys 
Biol 2012;9:016001.
 24. Nair VS, Keu KV, Luttgen MS, et al. An observational study of circulat-
ing tumor cells and (18)F-FDG PET uptake in patients with treatment-
naive non-small cell lung cancer. PLoS One 2013;8:e67733.
 25. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals 
with pulmonary nodules: when is it lung cancer? Diagnosis and man-
agement of lung cancer, 3rd ed: American College of Chest Physicians 
evidence-based clinical practice guidelines. Chest 2013;143(5 
Suppl):e93S–120S. 
 26. MacMahon H, Austin JH, Gamsu G, et al.; Fleischner Society. Guidelines 
for management of small pulmonary nodules detected on CT scans: a 
statement from the Fleischner Society. Radiology 2005;237:395–400.
 27. Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the 
management of subsolid pulmonary nodules detected at CT: a statement 
from the Fleischner Society. Radiology 2013;266:304–317.
 28. Ettinger DS, Akerley W, Borghaei H, et al.; NCCN (National 
Comprehensive Cancer Network). Non-small cell lung cancer. J Natl 
Compr Canc Netw 2012;10:1236–1271.
1119Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 8, August 2014 CTM Diagnostics in NSCLC
 29. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of 
the accuracy of a biomarker used for classification or prediction: stan-
dards for study design. J Natl Cancer Inst 2008;100:1432–1438.
 30. Rami-Porta R, Ball D, Crowley J, et al.; International Staging Committee; 
Cancer Research and Biostatistics; Observers to the Committee; 
Participating Institutions. The IASLC Lung Cancer Staging Project: 
proposals for the revision of the T descriptors in the forthcoming (sev-
enth) edition of the TNM classification for lung cancer. J Thorac Oncol 
2007;2:593–602.
 31. Shankar LK, Hoffman JM, Bacharach S, et al.; National Cancer Institute. 
Consensus recommendations for the use of 18F-FDG PET as an indicator 
of therapeutic response in patients in National Cancer Institute Trials. J 
Nucl Med 2006;47:1059–1066. 
 32. Tibshirani R. Regression shrinkage and selection via the lasso. J Royal 
Statist Soc B 1996;58:267–288.
 33. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for 
R and S+ to analyze and compare ROC curves. BMC Bioinformatics 
2011;12:77.
 34. Picard R, Cook D. Cross-validation of regression models. J Am Stat 
Assoc 1984;79:575–583.
 35. Ihaka S, Gentleman R. R: a language for data analysis and graphics.  
J Comput Graph Stat. 1996;5:299–314.
 36. Liotta LA, Saidel MG, Kleinerman J. The significance of hematog-
enous tumor cell clumps in the metastatic process. Cancer Res 1976; 
36:889–894.
 37. Brandt B, Junker R, Griwatz C, et al. Isolation of prostate-derived sin-
gle cells and cell clusters from human peripheral blood. Cancer Res 
1996;56:4556–4561.
 38. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the periph-
eral blood of all major carcinomas but not in healthy subjects or patients 
with nonmalignant diseases. Clin Cancer Res 2004;10:6897–6904.
 39. Pantel K, Denève E, Nocca D, et al. Circulating epithelial cells in patients 
with benign colon diseases. Clin Chem 2012;58:936–940.
 40. Ni X, Zhuo M, Su Z, et al. Reproducible copy number variation patterns 
among single circulating tumor cells of lung cancer patients. Proc Natl 
Acad Sci U S A 2013;110:21083–21088.
